Screening for prostate cancer: A controversy or fact

Hippokratia

Volumn 14, Issue 3, 2010, Pages 170-175

  Stavridis, S ^a   Saidi, S ^a   Lekovski, L J ^a   Dohcev, S ^a   Spasovski, G ^b  

^a SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

^b SS CYRIL AND METHODIUS UNIVERSITY OF SKOPJE   (Macedonia)

Author keywords

Advantages; Disadvantages; Prostate carcinoma; Review; Role; Schedule; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER GRADING; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CLINICAL DECISION MAKING; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; HUMAN; MEDLINE; MORBIDITY; PROSTATE CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME;

EID: 77954631284     PISSN: 11084189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007; 18: 581-592.
2. Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C. Leveling of prostate cancer mortality in Western Europe. Prostate. 2004; 60: 46-52.
3. Prostate Cancer: Cases, Prevalence, & Mortality. Crude and Age-Standardised (World) rates, per 100000, GLOBOCAN 2002, IARC Available from:http://www.urotoday.com/prod/con-tents/prosCan/cpm_namerica.asp:
4. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purifcation of a human prostate specifc antigen. Invest Urol. 1979; 17: 159-163.
5. Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC., et al Cancer surveillance series: interpreting trends in prostate cancer - part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999; 91: 1017-1024.
6. Rao AR, Motiwala HG, Karim OM. The discovery of prostate-specifc antigen. BJU Int. 2008;101: 5-10.
7. Brawer MK. Prostate specifc antigen. A review. Acta Oncol. 1991; 30:161-168.
8. Brawer MK, Lange PH. Prostate-specifc antigen in management of prostatic carcinoma. Urology. 1989; 33(5 Suppl):11-16.
9. Guess HA, Heyse JF, Gormley GJ. The effect of fnasteride on prostate-specifc antigen in men with benign prostatic hyperplasia. Prostate. 1993; 22:31-37.
10. Feuer EJ, Merrill RM, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer -part II: Cause of death misclassifcation and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst. 1999; 91: 1025-1032.
11. Sindhwani P, Wilson CM. Prostatitis and serum prostate-specifc antigen.Curr Urol Rep. 2005 Jul; 6: 307-312.
12. Loeb S, Gashti SN, Catalona WJ. Exclusion of infammation in the differential diagnosis of an elevated prostate-specifc antigen (PSA). Urol Oncol. 2009 Jan-Feb;27: 64-66.
13. Wilson JM, Jungner YG. Principles and practice of mass screening for disease. Bol Ofcina Sanit Panam. 1968; 65: 281-393.
14. de Koning HJ, Liem MK, Baan CA, Boer R, Schröder FH, Alexander FE. Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomized Screening for Prostate Cancer (ERSPC) trial. Int J Cancer. 2002; 98: 268-273.
15. Schroder FH, Denis LJ, Roobol M, Nelen V, Auvinen A, Tam-mela T, et al. The story of the European Randomized Study of Screening for Prostate Cancer. BJU Int. 2003; 92 Supp l2: 1-13.
16. Schröder FH. Screening for prostate cancer (PC)--an update on recent fndings of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Urol Oncol. 2008; 26: 533-541.
17. Candas B, Cusan L, Gomez JL, Diamond P, Suburu RE, Lévesque J, et al. Evaluation of prostatic specifc antigen and digital rectal examination as screening tests for prostate cancer. Prostate. 2000; 45: 19-35.
18. Scherr DS, Eastham J, Ohori M, Scardino PT. Prostate biopsy techniques and indications: when, where, and how? Semin Urol Oncol. 2002; 20: 18-31.
19. Punnen S, Nam RK. Indications and timing for prostate biopsy, diagnosis of early stage prostate cancer and its defnitive treatment: a clinical conundrum in the PSA era. Surg Oncol. 2009;18: 192-199.
20. Labrie F, Candas B, Dupont A, Cusan L, Gomez JL, Suburu RE, et al. Screening decreases prostate cancer death: frst analysis of the 1988 Quebec prospective randomized controlled trial. Prostate. 1999; 38: 83-91.
21. Labrie F, Candas B, Cusan L, Gomez JL, Bélanger A, Brous-seau G, et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate. 2004; 59:311-318.
22. Sandblom G, Varenhorst E, Lofman O, Rosell J, Carlsson P. Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomized controlled trial in Sweden. Eur Urol. 2004; 46: 717-723.
23. Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schönitzer D, et al. Prostate cancer mortality after introduction of prostate-specifc antigen mass screening in the Federal State of Tyrol, Austria. Urology. 2001; 58: 417-424.
24. Bartsch G, Horninger W, Klocker H, Pelzer A, Bektic J, Oberaigner W, et al. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int. 2008; 101: 809-816.
25. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specifc antigen level < or=4.0 ng per milliliter. N Engl J Med. 350, 2239-2246.
26. Kobayashi T, Nishizawa K, Ogura K, Mitsumori K, Ide Y. Detection of prostate cancer in men with prostate-specifc antigen levels of 2.0 to 4.0 ng/ml equivalent to that in men with 4.1 to 10. ng/ml in a Japanese population. Urology. 63: 727-731.
27. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006; 98: 529-534.
28. Pinsky PF, Crawford ED, Kramer BS, Andriole GL, Gelmann EP, Grubb R, et al. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial. BJU Int. 2007; 99: 775-779.
29. Pinsky PF, Andriole G, Crawford ED, Chia D, Kramer BS, Grubb R, et al. Prostate-specifc antigen velocity and prostate cancer gleason grade and stage. Cancer. 2007; 109: 1689-1695.
30. UK National Screening Committee. Second report of the UK National ScreeningCommittee.Availablefrom: http://www.library.nhs.uk/screening/ViewResource.aspx?resID=59835
31. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specifc antigen level < or =4.0 ng per milliliter. N Engl JMed. 2004; 350: 2239-2246.
32. Prabhakaran VM. Early detection of prostate cancer. Role of prostate-specifc antigen. Can Fam Physician. 1996; 42: 709-712.
33. Catalona WJ. Clinical utility of measurements of free and total prostate-specifc antigen (PSA): a review. Prostate Suppl. 1996; 7: 64-69.
34. van Iersel MP, Witjes WP, Thomas CM, Segers MF, Oosterhof GO, Debruyne FM. Review on the simultaneous determination of total prostate-specifc antigen and free prostate-specifc antigen. Prostate Suppl. 1996; 7: 48-57.
35. Loeb S, Catalona WJ. Prostate-specifc antigen in clinical practice. Cancer Lett. 2007; 249: 30-39.
36. Konstantinos H. Prostate cancer in the elderly. Int Urol Nephrol. 2005; 37: 797-806.
37. Gretzer MB, Partin AW. PSA markers in prostate cancer detection. Urol Clin North Am. 2003 Nov;30: 677-686.
38. Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Int Med. 2002; 137: 917-929.
39. Presti JC, Hovey R, Carroll PR, Shinohara K. Prospective evaluation of prostate specifc antigen density in the detection of nonpalpabile and stage T1c carcinoma of the prostate. J Urol. 1996; 156: 1685-1690
40. Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol. 1994; 152: 1714-1720.
41. Epstein JI, Sanderson H, Carter HB, Scharfstein DO. Utility of saturation biopsy to predict insignifcant cancer at radical prostatectomy. Urology. 2005; 66: 356-360.
42. Radwan MH, Yan Y, Luly JR, Figenshau RS, Brandes SB, Bhay-ani SB, et al. Prostate-specifc antigen density predicts adverse pathology and increased risk of biochemical failure. Urology. 2007; 69: 1121-1127.
43. Saidi S, Georgiev V, Stavridis S, Petrovski D, Dohcev S, Lekovs-ki L, et al. Does prostate specifc antigen density correlates with aggressiveness of the prostate cancer? Hippokratia. 2009; 13: 232-236.
44. Postma R, Schroder FH, van Leenders GJ, Hoedemaeker RF, Vis AN, Roobol MJ, et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC) - Section Rotterdam. A comparison of two rounds of screening. Eur Urol. 2007; 52: 89-97.
45. Schröder FH, vander Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Prostate cancer detection at low prostate specifc antigen. J Urol. 2000; 163: 806-812.
46. Schroder FH, van der Maas P, Beemsterboer P, Kruger AB, Ho-edemaeker R, Rietbergen J, et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 1998; 90: 1817-1823.
47. Gosselaar C., Roobol M.J., van den Bergh RC, Wolters T, Schröder FH. Digital Rectal Examination and the Diagnosis of Prostate Cancer-a study Based on 8 Years and Three Screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC),Rotterdam. Eur Urol. 2009; 55:139-147.
48. Roobol MJ, Grenabo A, Schroder FH, Hugosson J. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. J Nat Cancer Inst. 2007; 99: 1296-1303.
49. Kattan MW. A nomogram for predicting 10-year life expectancy in men with prostate cancer after defnitive therapy. Nat Clin Pract Urol. 2008; 5:138-139.
50. vander Cruijsen-Koeter I W, Vis A N, Roobol M J, Wildhagen M F, de Koning H J, van der Kwast T H, et al. Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam. J Urol. 2005; 174:121-125.
51. Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer - results from a prospective, population-based randomized controlled trial. Eur Urol. 2007; 51: 659-664.
52. Vercelli M, Quaglia A, Marani E, Parodi S. Prostate cancer incidence and mortality trends among elderly and adult Europeans. Crit Rev Oncol Hematol. 2000; 35: 133-144.
53. Postma R, van Leenders AG, Roobol MJ, Schröder FH, van der Kwast TH. Tumour features in the control and screening arm of a randomized trial of prostate cancer. Eur Urol. 2006; 50: 70-75.
54. Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol. 1990; 143: 742-746.
55. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, et al. Lead times and overdetection due to prostate-specifc antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Can cer Inst. 2003; 95: 868-878.
56. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical fndings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994; 271: 368-374.
57. Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ, Schröder FH. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol. 2007; 177: 107-112.
58. Epstein JI, Chan DW, Sokoll LJ, Walsh PC, Cox JL, Rittenhouse H, et al. Nonpalpable stage T1c prostate cancer: prediction of insignifcant disease using free/total prostate specifc antigen levels and needle biopsy fndings. J Urol. 1998; 160(6 Pt 2): 2407-2411.
59. Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schrder FH, et al. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology. 2002; 60: 826-830.
60. Rietbergen JB, Kruger AE, Kranse R, Schröder FH. Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program. Urology. 1997; 49: 875-880.
61. Madalinska JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Maas PJ, Schröder FH. Healthrelated quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol. 2001; 19:1619-1628.
62. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2009; 59: 27-41.
63. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines on prostate cancer. European Association of Urology. Eur Urol. 2008; 53: 68-80. Epub. 2007 Sep 19.
64. Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H, et al. EAU guidelines on prostate cancer. European Association of Urology. Eur Urol. 2005; 48: 546-551.
65. Thompson I, Thrasher JB, Aus G. J Urol. Guideline for the management of clinically localized prostate cancer: 2007 update. 2007; 177: 2106-2131.